인사이트
Insights From Our Experts
Articles
Pharmaceutical Distribution – Right-Sizing the Channel Strategy for Maximum Impact
In recent years, there has been increasing appetite among manufacturers — and growing capabilities among specialized channel-distribution service providers — to shorten the value chain. When drug manufacturers reflexively commit to a distribution model that is…
WEBINAR: Innovative Pharmacy and Distribution Models Driven by Market Dynamics, Product Type, Site of Care and Reimbursement
The landscape of the pharmaceutical distribution industry is shifting from a familiar state to a novel market calling for a new level of channel service due to forces of innovation. In this webinar, EVERSANA’s Scot Buchanan,…
EPP Keynote Address: Global Pricing and Market Access Hurdles for Innovation
Global Pricing and Market Access Hurdles for Innovation In a recent keynote address at the 2021 EPP Life Sciences Pricing Conference, Alan Crowther, General Manager, EVERSANA Pricing and Market Access, discusses 4 hurdles that are serving…
Ask the Expert: e-Commerce Solutions for Channel Management
Many manufacturers involuntarily commit to convoluted, costly distribution models that often lack the flexibility needed to increase efficiency, maximize investments and minimize risk on a product-by-product basis. In this traditional model of working exclusively with large…
EPP Studio Live Webinar — Impact of COVID-19 Pandemic on German Healthcare System
Leading up to the recent German elections, the topic of healthcare took center stage for the aging German population. With nearly 90% of the population participating in Statutory Health Insurance (SHI), increased financial pressures have widened…
EPP Studio Live Webinar — EU Joint Procurement of COVID-19 Vaccines: A Model for Future Market Access in Europe?
The COVID-19 pandemic has changed the way we live and the way we respond to global healthcare crises. During this EPP Studio Live webinar, Douglas Foerster, Senior Vice President of Pricing & Market Access for EVERSANA,…
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma…
Competitive Benchmarking In Trade – Answering The Who, What, Why and When
Last month our colleague Derek Cothran addressed the importance of using secondary research to benchmark your Patient Support Program (PSP) against obvious and not-so-obvious competitors. We’d like to continue a discussion around competitive benchmarking in this…
Reinventing Launch: The Gold Standard Of Drug Commercialization
In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA's complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of…
Alternative Product Distribution Model: Where Agility Meets Profitability
Distributing innovative, life-altering therapies to patients is no small feat, and manufacturers shouldn’t settle for the status quo of an outdated, one-size-fits-all model. As you develop your channel strategy, consider how your distribution model can benefit…